B cell translocation gene 2 (BTG2) is a p53 target that negatively regulates cell cycle progression in response to DNA damage and other stress. The objective of this study was to examine the expression, regulation and tumor suppressor properties of BTG2 in prostate cells. By immunohistochemistry BTG2 protein was detected in approximately 50% of basal cells in benign glands from the peripheral zone of the human prostate. BTG2 was expressed in all hyperproliferative atrophic peripheral zone lesions examined (simple atrophy, post-atrophic hyperplasia and proliferative inflammatory atrophy), but was undetectable or detectable at very low levels in the hyperproliferative epithelial cells of HGPIN and prostate cancer. BTG2 mRNA was detected in non-malignant prostate epithelial (PE) cells and in LNCaP cells, but not in PC-3 cells, consistent with p53-dependent regulation. In PE cells BTG2 protein was detected in areas of cell confluence by immunohistochemistry. BTG2 protein in LNCaP cells was undetectable by immunohistochemistry but was detected by immunoblotting at 8- to 9-fold lower levels than in PE cells. BTG2 protein levels were shown to be regulated by the ubiquitin-proteosome system. Forced expression of BTG2 in PC-3 cells was accompanied by a decreased rate of cell proliferation and decreased tumorigenicity of these cells in vivo. Taken together, these findings suggest that BTG2 functions as a tumor suppressor in prostate cells that is activated by cell quiescence, cell growth stimuli as part of a positive feedback mechanism and in response to DNA damage or other cell stress. The low steady-state levels of BTG2 protein in HGPIN and prostate cancer, a potential consequence of increased proteosomal degradation, may have important implications in the initiation and progression of malignant prostate lesions. Furthermore, these findings suggest that a significant component of the p53 G(1) arrest pathway might be inactivated in prostate cancer even in the absence of genetic mutations in p53.
OBJECTIVE
To evaluate the results of the retrograde endoscopic treatment of upper urinary tract urothelial malignancies (UUTUM) in an attempt to preserve renal function while also obtaining an acceptable oncological result.
PATIENTS AND METHODS
Since 1995, 63 patients who were referred for retrograde endoscopic management of UUTUM were evaluated and treated. All patients had an initial diagnostic ureteroscopy and biopsy to obtain histopathological grading. Additional imaging studies were obtained to exclude metastatic disease. The treatment was directed by tumour grade at presentation and medical comorbidity. Tumour volume and multifocality did not exclude patients from vigorous endoscopic treatment. Tumours were resected with electrocautery, holmium‐YAG and Nd:YAG laser. Follow‐up endoscopic surveillance was initially at 3‐month intervals, with increasing intervals in patients with repeatedly negative findings.
RESULTS
The tumour grade at presentation was high in 14 (22%), moderate in six (10%), low in 35 (55%) and carcinoma in situ in eight (13%), with 13 (20%) presenting with or subsequently developing bilateral disease. Twenty patients had a nephroureterectomy as they were not amenable to endoscopic treatment. Medical comorbidities necessitated palliative endoscopic therapy of high‐grade tumour in six patients; the remaining 35 had low‐grade tumour and were managed with retrograde endoscopic therapy. Recurrent low‐grade disease was identified in 24 with a mean (range) time to recurrence of 15 (3–63) months. There was concurrent low‐grade bladder cancer in 21 (60%) of the patients. The mean (range) follow‐up was 32 (3–84) months. No patient with low‐grade tumour progressed in grade or stage, and all but one who presented with high‐grade tumour progressed.
CONCLUSION
The retrograde endoscopic management of UTTUMs is particularly useful for patients who present with low‐grade lesions, providing good oncological control and preserving renal function. These patients require a careful and consistent follow‐up, as many will develop recurrent disease. Treatment of higher‐grade lesions is at best palliative.
Objective
Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. We sought to determine whether Rezūm is effective in the treatment of catheter‐dependent urinary retention secondary to BPH.
Methods
A retrospective chart review was conducted on consecutive patients who presented for urinary retention and subsequently treated with Rezūm. We evaluated procedural details and examined variables pre‐ and post‐Rezūm (at 6 months) including International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS–QOL), maximum flow (Qmax), post void residual volume (PVR), prostate specific antigen, rate of retention, and use of alpha blockers and 5‐alpha reductase inhibitor (5ARI).
Results
Of the 49 patients included in this study, median age of was 73 years, median prostate volume was 73cc (Interquartile range [IQR]: 50, 103) and a median lobe was present in 80% of patients. All patients were in urinary retention before treatment with a median PVR of 900 ml (IQR: 566, 1146). Following Rezum, IPSS (17 pre‐Rezūm, 4 post‐Rezūm) and IPSS–QOL (4 pre‐Rezūm, 1 post‐Rezūm) both improved at 6 months (p < 0.01). Qmax increased from 3 to 6 ml/s (p = 0.03) and PVR decreased from 900 to 78 ml (p < 0.01). Only 17/38 patients taking alpha‐blockers and 7/15 patients on 5ARIs continued therapy at 6 months following Rezūm (p < 0.01). Of the 49 patients treated, 10 (20.4%) remained in catheter dependent urinary retention following the procedure, and 6 remained in retention at 6 months (12.2%) even after further surgical therapies for BPH (p < 0.01).
Conclusion
Rezūm is a safe and effective therapy for treating catheter dependent urinary retention in patients with BPH, including those with median lobes. As a minimally invasive therapy, it is a promising option in patient, particularly those who are not suitable for prolonged anesthesia.
RESULTS: No treatment-or device-related de novo erectile dysfunction occurred after treatment with iTind. International Index of Erectile Function (IIEF) and sexual health inventory for men (SHIM) scores were not different from the control group at 3 months or from baseline at 1 year. There was a statistically and clinically significant improvement of total IIEF from baseline to 12 months follow-up in both younger patients (45-60yrs) and also in patients with a baseline SHIM of !21 of 8.1 AE 16.83 (p[0.024) and 6.07 AE 21.17 (p[0.034), respectively.CONCLUSIONS: iTind for treatment of LUTS secondary to BPH preserves sexual and ejaculatory function regardless of a man's age, prostate volume, and baseline sexual function. In select groups, such as patients aged 45-60 or with no previous ED, sexual function may be modestly improved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.